Please assess the completion status of the following clinical trial:

Trial Title: A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria (Healthy Volunteers):~* Subject is male or female 18 to 55 yrs old~* Subject has a BMI 18 to 32 kg/m\^2~* Female and male subjects must use effective method of birth control~* Female subjects must have negative pregnancy test prior to first dose of study drug~* Subject must not have any clinically significant history or presence of ECG findings~* Subject must be in good general health~Inclusion Criteria (PA or MMA Patients):~* Patient is male or female 15 to 55 yrs old~* Patient has a BMI 18 to 32 kg/m\^2~* Female and male patients must use effective method of birth control~* Female patients must have negative pregnancy test prior to first dose of study drug~* Patient must have confirmed PA or MMA diagnosis~* Patient with MMA must have elevated plasma MMA levels~* Patient is willing to provide access to medical records for the last 6-12 months of care prior to study initiation~* Patient is on consistent disease management and treatment regimen is stable for at least 30 days prior to study initiation.~Exclusion Criteria (Healthy Volunteers):~* Subject has used prescription drugs (contraceptive medications are allowed) within 4 weeks before first dose of study drug or over-the-counter medication within 7 days of the first dose of study drug~* Subject who is unable or unwilling to refrain from wearing contact lenses during participation in the study.~* Subject has a history of dry eye or eye surgery, including radial keratotomy and LASIK surgery.~* Subject who has taken the COVID-19 vaccine, the last vaccine dose must be at least 14 days prior to first dose of study drug.~* Subject has abnormal laboratory test results~* Subject has a baseline eGFR \<90 mL/minute~* Subject has positive result for Hepatitis B, Hepatitis C, or HIV~* Female subject is non-pregnant and non-lactating~* Subject is a smoker or has used nicotine or nicotine-containing products~* Subject has a history of alcohol or drug abuse within 12 months prior to first dose of study drug and/or has a positive result prior to dosing or throughout the study~* Subject has donated blood or blood products \>450mL within 30 days prior to study drug dosing~* Subject has a history of relevant drug or food allergies~* Subject has received study drug in another investigational study within 30 days of dosing~* Subject has undergone prior liver and/ or kidney transplant.~Exclusion Criteria (PA or MMA Patients):~* Patient has used prescription drugs (contraceptive medications are allowed) within 4 weeks before first dose of study drug or over-the-counter medication within 7 days of the first dose of study drug that is not part of their PA or MMA disease management and treatment~* Patient who has taken the COVID-19 vaccine, the last vaccine dose (or booster) must be at least 14 days prior to first dose of study drug.~* Patient is unable or unwilling to refrain from wearing contact lenses during participation in the study.~* Patient has a history of dry eye or eye surgery, including radial keratotomy and LASIK surgery.~* Patient has clinically significant abnormal laboratory test results unrelated to PA or MMA~* Patient has a baseline eGFR \<60 mL/minute~* Patient has positive result for Hepatitis B, Hepatitis C, or HIV~* Female patient is non-pregnant and non-lactating~* Patient has a history of alcohol or drug abuse within 12 months prior to first dose of study drug and/or has a positive result prior to dosing or throughout the study~* Patient has donated blood or blood products \>450mL within 30 days prior to study drug dosing~* Patient has a history of relevant drug or food allergies~* Patient has received study drug in another investigational study within 30 days of dosing~* PA patient has undergone prior liver and/ or kidney transplant. Prior liver and/or kidney transplant is allowed for patients with MMA.~* Patient has had a recent infection requiring system antibiotics within 4 weeks of Baseline or any active infection that precludes the patient from participation~* Patient has Grade 3 or 4 heart failure according to the Modified Ross Heart Failure Classification for Children or the New York Heart Association.~* Patient has been exposed to gene therapy for PA or MMA at any time prior to study entry.~* Patient is currently taking sensitive CYP3A4 substrates (e.g., tacrolimus or sirolimus)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BBP-671 for SAD (Type: EXPERIMENTAL): The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
- Placebo for SAD (Type: PLACEBO_COMPARATOR): The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
- BBP-671 for MAD (Type: EXPERIMENTAL): The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
- Placebo for MAD (Type: PLACEBO_COMPARATOR): The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
- BBP-671 for SAD Food Effect (Type: EXPERIMENTAL): Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
- BBP-671 for PA and MMA Patients (Type: EXPERIMENTAL): Up to sixteen (16) patients with either PA or MMA will receive BBP-671.

Based on this trial design, predict the completion outcome and termination type (if applicable).